Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | TLR4 | O00206 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6514709 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2HSD17B10HDAC8HDAC6CES2 | |
| SCHEMBL6523448 | 0.82 | CES2 (0.34) | SMN1; SMN2HSD17B10HDAC8HDAC6CES2 | |
| SCHEMBL6523453 | 0.82 | CES2 (0.34) | SMN1; SMN2HSD17B10HDAC8HDAC6CES2 | |
| SCHEMBL6516582 | 0.81 | EPHX2 (0.37) | SMN1; SMN2HSD17B10HDAC8HDAC6CES2 | |
| SCHEMBL6516574 | 0.81 | EPHX2 (0.37) | SMN1; SMN2HSD17B10HDAC8HDAC6CES2 | |
| SCHEMBL6524001 | 0.81 | CES2 (0.38) | SMN1; SMN2HSD17B10HDAC8HDAC6CES2 | |
| SCHEMBL6513745 | 0.81 | CES2 (0.38) | SMN1; SMN2HSD17B10HDAC8HDAC6CES2 | |
| SCHEMBL6523993 | 0.81 | CES2 (0.38) | SMN1; SMN2HSD17B10HDAC8HDAC6CES2 | |
| SCHEMBL6513755 | 0.81 | CES2 (0.38) | SMN1; SMN2HSD17B10HDAC8HDAC6CES2 | |
| SCHEMBL6520968 | 0.80 | NAAA (0.36) | SMN1; SMN2HSD17B10HDAC8HDAC6CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958366-B2 | Antifouling coating composition and novel resin | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2005-10-25 | — | — | US | disclosed |
| US-20030118544-A1 | Antifouling coating composition and novel resin | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030118544-A1 | Antifouling coating composition and novel resin | COL1A1, GLRA1, COL2A1 | SMN1; SMN2 1768/4885HSD17B10 2626/4885HDAC8 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.